Stoke Therapeutics Doses The First Patient In Phase 1 OSPREY Study Of STK-002 For Autosomal Dominant Optic Atrophy

Stoke Therapeutics -0.56%

Stoke Therapeutics

STOK

35.34

-0.56%

  • Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA.
  • Changes in visual function, ocular structure and quality of life to be evaluated as secondary objectives.
  • ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in progressive and irreversible vision loss